Beyond AMR, Biogen is planning to initiate phase 3 trials of felzartamab in two kidney diseases, IgA nephropathy and primary ...

Dr Andrew Bomback comments on how disparities in access to healthcare significantly delay the diagnosis and treatment of IgA ...

Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home ...

Dr Pietro Canetta reflects on how the rapidly advancing field of IgA nephropathy research has transformed from limited ...

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was ...

World Kidney Day was observed at GMCH highlighting the escalating prevalence of Chronic Kidney Disease (CKD) in Assam. Physicians emphasize the need for further investigation into CKD's unknown ...

Guwahati: Physicians at Gauhati Medical College and Hospital (GMCH) have flagged elevated instances of Chronic Kidney Disease ...

Haseeb Ahmad brings over 25 years of leadership experience in life sciences, most recently serving as President of Novartis ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic ...

Travere Therapeutics' Filspari boosts revenue with FDA approval, but heavy losses and competitive threats raise concerns for ...

Arrowhead (ARWR) announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference ...